High Dose Chemotherapy and Autologous Transplant for Breast Cancer

Stanford University203 enrolled

Overview

To determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

203

Conditions

Graft vs Host Disease

Interventions

high dose chemo and auto hematopoietic cell transplantPROCEDURE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Stage II, III or IV breast cancer * chemosensitive * adequate organ function Exclusion Criteria: * prior transplant, * life threatening disease * brain metastases

Locations (1)

Stanford University Cancer Center

Stanford, California, United States

Outcomes

Primary Outcomes

Survival

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.